ArticleFrontiers in pharmacology2025
Effectiveness of infection control measures informed by a modified Blue-Carba test in reducing rectal carriage of carbapenemase-producing bacteria in general wards: a prospective interrupted time series study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Introduction: The spread of carbapenemase-producing bacteria (CPB) is exacerbated in hospital settings, making the surveillance of rectal carriage of CPB crucial to halt their spread. However, the processing time until detection with traditional methods and the cost of new techniques limit their implementation. We aimed to evaluate the effectiveness of infection prevention and control (IPC) measures guided by a novel algorithm (NA) for rectal swab processing, which incorporated a modified Blue-Carba test (mBCT), in reducing carbapenemase-producing bacteria (CPB) rectal carriage prevalence in general wards of a tertiary-care hospital from Argentina. Additionally, we assessed the impact of this algorithm on microbiological turnaround time (mTAT) and time to positive results (TPR). Materials and methods: An experimental and quasi-experimental designs were combined into a prospective interrupted time series study structured in three phases: P1 (February 2022-July 2022), P2 (August 2022-January 2023; intervention) and P3 (February 2023-July 2023). Briefly, the NA included as key steps a 6-hour pre-incubation at 37 °C in nutrient broth, followed by a 15-minute centrifugation at 3,200 rpm. The mBCT was set at pH 10.7 using 9 mg of imipenem in a final volume of 150 μL and was validated against conventional methods testing 1,120 samples. It was subsequently implemented to assess its impact on hospital CPB prevalence and the effectiveness of IPC measures. Patients were randomly selected for CPB rectal screening during Phases 1 and 3 and provided informed consent for inclusion. Results: The mBCT significantly shortened the mTAT and TPR compared to standard approaches (<24 h vs. 4d, p < 0.001), showing moderate sensitivity [54.6% (IC95% 45.2-63.7)] and high specificity [99.8% (IC 95% 99.3-100)]. The IPC intervention guided by the mBCT reduced CPB prevalence in general wards (8.1% vs. 13.8%, p = 0.006). Conclusion: The implementation of the NA reduced mTAT with high sensitivity, while the mBCT also contributed to reducing TPR with high specificity. Integrating the NA and mBCT into IPC protocols led to a decrease in CPB rectal carriage prevalence in general wards, underscoring their diagnostic, epidemiological and thus IPC benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.